Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

245 participants

Study Classification

OBSERVATIONAL

Study Start Date

2022-12-01

Study Completion Date

2024-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

IgA nephropathy accounts for about 45 per cent of primary glomerular diseases in China and about 26 per cent of renal biopsies in patients with chronic failure.According to current guideline recommendations, there are limited indications for non-steroidal MRAs. Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Effect of Finerenone in IgA Nephropathy

NCT06580288

IgA Nephropathy

NOT_YET_RECRUITING PHASE3

Finerenone in Patients With IgA-nephropathy: Prospective Interventional Trial

NCT07056595

IgA Nephropathy (IgAN)

RECRUITING NA

Efficacy and Safety of Finerenone in Patients With Primary Membranous Nephropathy

NCT06573411

Primary Membranous Nephropathy

NOT_YET_RECRUITING PHASE4

Effect of Finerenone in Patients With Non-diabetic Glomerulonephritis

NCT06835322

Glomerulonephritis

RECRUITING PHASE2

Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy

NCT02662283

IGA Nephropathy

UNKNOWN PHASE2/PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Primary IgA nephropathy (IgAN) is an immunopathological diagnostic term for a type of glomerulonephritis characterised by the deposition of IgA or IgA-dominant immune complexes in the glomerular tunica albuginea. And in China IgA nephropathy accounts for about 45% of primary glomerular diseases and about 26% of renal biopsies in patients with chronic failure. Among them, about 15-40% of IgA nephropathy patients progress to renal failure after 10-20 years; IgA nephropathy has become one of the main causes of end-stage renal failure.The nonsteroidal salicorticoid receptor antagonist (MRA)- finerenone reduces the risk of composite renal outcomes, ESKD, or renal death in patients with type 2 diabetes and CKD.There are limited indications for non-steroidal MRAs. Therefore clinical studies to explore the range of clinical indications for fenetyllone are warranted.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Finerenone IgA Nephropathy Proteinuria Safety Issues

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Immune Suppressant

Receive immune suppressant treatment as specified in the KDIGO guidelines

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

FINE RASI immunosupressive

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* primary IgAN diagnosed by renal biopsy;
* receive RASI inhibitors for at least 3 months;
* serum potassium \<5 mmol/L;
* protein-to-creatinine ratio (PCR) \>0.3 mg/g

Exclusion Criteria

* secondary IgAN;
* autosomal dominant polycystic kidney disease or autosomal recessive polycystic kidney disease, lupus nephritis, lupus nephritis,;
* previous renal transplantation;
* chronic hepatic disease, malignant tumor, active malignancy, heart failure with ejection fraction \<40%;
* followed up less than 6 months;

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No